On May 10, 2018, the Colorado Department of Public Health and Environment (CDPHE) was notified by Children’s Hospital Colorado (CHCO) of an increase in pediatric cases of meningitis and encephalitis in which patients tested positive for enterovirus (EV). CDPHE surveillance data for May 2018 showed a 2.75-fold increase in encephalitis of unknown etiology compared with the 5-year (May 2013–2017) average; this coincided with a threefold rise in enterovirus/rhinovirus (EV/RV) detections from clinical testing at CHCO during the same period. Specimens from children with neurologic disease were tested by EV reverse transcription–polymerase chain reaction (RT-PCR) at CHCO and VP1 sequencing at CDC (). As of August 26, 2018, EV-A71 was identified in 34 children with neurologic disease. This report describes the clinical, laboratory, and radiologic findings for the first 13 children identified with EV-A71 neurologic disease for whom complete information is available.Patients with EV-A71 central nervous system (CNS) infection had symptom onset during March 10–June 5, 2018; median age was 13 months (range = 10 days–35 months); 11 were male. Twelve had meningitis, nine had encephalitis, and three had acute flaccid myelitis (AFM). All 13 children had fever and irritability; three developed lesions typical of hand, foot, and mouth disease. Neurologic signs included encephalopathy (seven), ataxia (seven), myoclonus (six), limb weakness (four), cranial nerve deficits (two), and seizures (one). Nine of 10 children with a cerebrospinal fluid (CSF) specimen analyzed had a pleocytosis (median white blood cell count = 106 cells/μL, range = 17–698 [normal = 0–5]). Six of eight children who had brain imaging results had abnormalities; five were in the brainstem, three in the cerebellum, and three in the spinal cord. All 13 children had EV-A71 identified in nasopharyngeal, pharyngeal, or rectal specimens. However, only two of 11 children whose CSF was tested had a specimen positive for enterovirus by pan-EV RT-PCR; one of two was available for typing and was identified as EV-A71. All 13 children were hospitalized (median = 5 days; range = 1–23 days), and four required intensive care. The three children who received an AFM diagnosis had residual limb weakness at discharge. All children survived.EV-A71 can cause hand, foot, and mouth disease and neurologic disease, primarily among children aged <5 years (,). Common manifestations include a febrile illness with lesions on the palms, soles, oral mucous membranes, or perineum; and aseptic meningitis. Severe CNS EV-A71 infection can cause brainstem encephalitis leading to cardiopulmonary collapse and polio-like AFM (). EV-A71 epidemics have occurred in the Asian-Pacific region since the late 1990s (). Since the 1980s, the National Enterovirus Surveillance System has detected seasonal endemic EV-A71 activity in the United States; EV-A71 accounts for <1% of typed EVs (). Limited, regional U.S. outbreaks have occurred sporadically in an unpredictable pattern; factors causing year-to-year circulation have not been identified (,). Peak U.S. circulation of EVs, including EV-A71, usually occurs during June–October (,). Although associated with neurologic disease, EV-A71 is uncommonly detected in CSF and is more frequently identified in respiratory and fecal specimens (). In similar EV-A71 outbreaks in Colorado during 2003 and 2005, EV-A71 CNS infection was identified in 16 children (eight in each cluster); 11 children recovered fully, four had residual limb paralysis, and one child died (). At this time, no other clusters of EV-A71 neurologic disease have been reported to CDC in 2018.This investigation highlights the importance of testing nonsterile sites when CNS disease associated with EV is suspected and CSF is negative. Furthermore, health care providers should consider EV-A71 as an etiology when febrile patients display myoclonus, ataxia, or limb weakness. CDPHE has alerted Colorado health care providers to the EV-A71 outbreak and requested reports of EV meningitis and encephalitis, in addition to routine AFM surveillance.
Authors: Tom Solomon; Penny Lewthwaite; David Perera; Mary Jane Cardosa; Peter McMinn; Mong How Ooi Journal: Lancet Infect Dis Date: 2010-10-18 Impact factor: 25.071
Authors: Carlos M Pérez-Vélez; Marsha S Anderson; Christine C Robinson; Elizabeth J McFarland; W Allan Nix; Mark A Pallansch; M Steven Oberste; Mary P Glodé Journal: Clin Infect Dis Date: 2007-09-13 Impact factor: 9.079
Authors: Margarita Pons-Salort; M Steven Oberste; Mark A Pallansch; Glen R Abedi; Saki Takahashi; Bryan T Grenfell; Nicholas C Grassly Journal: Proc Natl Acad Sci U S A Date: 2018-03-05 Impact factor: 11.205
Authors: Matthew J Elrick; Eliza Gordon-Lipkin; Thomas O Crawford; Keith Van Haren; Kevin Messacar; Nicole Thornton; Elizabeth Dee; Annie Voskertchian; Jessica R Nance; Laura S Muñoz; Mark P Gorman; Leslie A Benson; David L Thomas; Carlos A Pardo; Aaron M Milstone; Priya Duggal Journal: JAMA Pediatr Date: 2019-02-01 Impact factor: 16.193
Authors: Olwen C Murphy; Kevin Messacar; Leslie Benson; Riley Bove; Jessica L Carpenter; Thomas Crawford; Janet Dean; Roberta DeBiasi; Jay Desai; Matthew J Elrick; Raquel Farias-Moeller; Grace Y Gombolay; Benjamin Greenberg; Matthew Harmelink; Sue Hong; Sarah E Hopkins; Joyce Oleszek; Catherine Otten; Cristina L Sadowsky; Teri L Schreiner; Kiran T Thakur; Keith Van Haren; Carolina M Carballo; Pin Fee Chong; Amary Fall; Vykuntaraju K Gowda; Jelte Helfferich; Ryutaro Kira; Ming Lim; Eduardo L Lopez; Elizabeth M Wells; E Ann Yeh; Carlos A Pardo Journal: Lancet Date: 2020-12-23 Impact factor: 79.321
Authors: Margaret M Cortese; Anita K Kambhampati; Jennifer E Schuster; Zaid Alhinai; Gary R Nelson; Gloria J Guzman Perez-Carrillo; Arastoo Vossough; Michael A Smit; Robert C McKinstry; Timothy Zinkus; Kevin R Moore; Jeffrey M Rogg; Meghan S Candee; James J Sejvar; Sarah E Hopkins Journal: PLoS One Date: 2020-02-13 Impact factor: 3.240
Authors: Jie Kai Tan; Ran Chen; Regina Ching Hua Lee; Feng Li; Kun Dai; Guo-Chun Zhou; Justin Jang Hann Chu Journal: Pharmaceuticals (Basel) Date: 2022-01-18
Authors: Margarita Del Cuerpo; Jon Gonzalez de Audicana; Maria Dolores Fernandez-Garcia; Pilar Marín; Montserrat Esteban; Montserrat Español; María Cabrerizo; Núria Rabella Journal: Microorganisms Date: 2022-03-09